PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8748003

Stem cell cryopreservation.

J Gorlin
View original source ↗Export metadata ↓

Abstract

The recent widespread use of protocols, including high dose chemotherapy with peripheral blood progenitor cell rescue, has resulted in increased demand for cryobiological services to freeze and thaw the collected progenitors. This has led to reexamination of many cryobiological practices and proposal of alternative methodologies. This review examines the scientific bases of cryobiological practices, how cryoprotectants work and alternative methods of freezing and thawing. Finally, while blood banks have come under tremendous regulatory pressure from federal agencies, hematopoietic stem cell processing has been relatively unburdened by such regulation to date. Recent meetings between the FDA and interested organizations make it clear that this largesse is coming to an end. Hence many organizations are promulgating standards that apply to marrow and peripheral stem cell processing.

Explore related subjects

Blood PreservationCryopreservationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHumansJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Gorlin. 1996. Stem cell cryopreservation.. https://pubmed.ncbi.nlm.nih.gov/8748003/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Improved removal of white cells with minimal platelet loss by filtration of apheresis platelets during collection.

BACKGROUND: Filtration of apheresis platelets to remove white cells (WBCs) requires operator intervention after the collection procedure (postcollection filtration), which may cause variable and unsatisfactory filter performance (WBC removal and platelet loss). The MCS+ LN9000 apheresis system filters platelets through a WBC-reduction filter during each collection cycle (continuous filtration) at a flow rate of 15 to 25 mL per minute. Apheresis platelets obtained by continuous filtration were evaluated in terms of platelet loss, WBC removal, and platelet storage properties and then were compared to unfiltered apheresis platelets and to apheresis platelets that underwent postcollection filtration. Two WBC-reduction filters were tested (LRF6 and LRFXL). STUDY DESIGN AND METHODS: In 70 apheresis platelets, postcollection filtration was performed by using the LRF6 at flow rates of 80 mL per minute (n = 30) and 50 mL per minute (n = 30) and the LRFXL at 50 mL per minute (n = 10). One hundred fifty-eight apheresis platelets underwent continuous filtration through the LRF6 (n = 58) or the LRFXL (n = 100). Unfiltered apheresis platelets (controls) (n = 30) were obtained by the same collection protocol. RESULTS: Estimated platelet loss with continuous filtration was 7 percent for the LRFXL and 3 percent for the LRF6. A reduction in the filtration flow rate from 80 to 50 mL per minute with postcollection filtration through the LRF6 resulted in markedly lower WBC levels, with 10 percent versus 57 percent of the apheresis platelets having WBC counts <1 x 10(5), respectively. Additional improvements in WBC removal were found with continuous filtration; 85 percent of the apheresis platelets filtered with the LRF6 and 100 percent of the apheresis platelets filtered with the LRFXL had WBC counts <1 x 10(5). CONCLUSIONS: Continuous or postcollection filtration of freshly collected apheresis platelets resulted in minimal platelet loss. Better WBC removal from apheresis platelets was obtained with continuous filtration than with postcollection filtration, likely because of the slower flow rate. Platelet storage quality was not affected by filtration.

Blood Preservation↗
PubMed1999

Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study.

The Multicenter AIDS Cohort Study (MACS), an ongoing prospective study of the natural history of human immunodeficiency virus (HIV), has stored biologic specimens, including peripheral blood mononuclear cells (PBMC), from 5,622 participants for up to 12 years. The purpose of the present analysis was to evaluate the quality of the PBMC in the MACS repository in order to test the validity and feasibility of nested retrospective studies and to guide the planning of future repositories. PBMC were collected from MACS participants at four centers at 6-month intervals from 1984 to 1995, cryopreserved, and transported to a central repository for storage. A total of 596 of these specimens were subsequently tested for viability and used to evaluate cell function, to conduct immunophenotype analysis, or to isolate HIV. Simple linear regression models were applied to evaluate trends in recovery and viability over time and by center. Results indicated that from a nominal 10(7) cells cryopreserved per vial at all four centers, the median number of viable cells recovered was at least 5 x 10(6) (50% of the number stored) and the median viability was at least 90%. Results suggested that cryopreserved cells can be stored for at least 12 years with no general tendency toward cell loss over time. Furthermore, there were no statistically significant changes in the percent cell viability according to the length of time frozen, regardless of HIV serostatus or the level of CD4(+) lymphocytes. Storing 10(7) PBMC per vial yields sufficient viable cells for phenotypic and/or functional analysis. Results from the MACS provide the basis for the planning of future repositories for use by investigators with similar research goals.

Blood Preservation↗